162 related articles for article (PubMed ID: 25203944)
1. [Regarding the article: "Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort"].
de Sá J
Acta Med Port; 2014; 27(4):409-10. PubMed ID: 25203944
[No Abstract] [Full Text] [Related]
2. Body weight-based natalizumab treatment in adult patients with multiple sclerosis.
Tanaka M; Kinoshita M; Foley JF; Tanaka K; Kira J; Carroll WM
J Neurol; 2015 Mar; 262(3):781-2. PubMed ID: 25663410
[No Abstract] [Full Text] [Related]
3. Localized sporotrichosis during natalizumab treatment in Multiple Sclerosis.
Marques PT; Kay CSK; Basílio FMA; Pinheiro RL; Werneck LC; Lorenzoni PJ; Scola RH
Mult Scler Relat Disord; 2020 Jun; 41():102029. PubMed ID: 32155462
[No Abstract] [Full Text] [Related]
4. Altering the course of disease in multiple sclerosis: many large steps forward.
Fragoso YD
Arq Neuropsiquiatr; 2015 Sep; 73(9):731-2. PubMed ID: 26352487
[No Abstract] [Full Text] [Related]
5. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
Shirani A; Stüve O
J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
[TBL] [Abstract][Full Text] [Related]
6. Developing a Model of Care for Home Infusions of Natalizumab for People With Multiple Sclerosis.
Schultz TJ; Thomas A; Georgiou P; Cusack L; Juaton M; Simon L; Naidoo K; Webb K; Karnon J; Ravindran J
J Infus Nurs; 2019; 42(6):289-296. PubMed ID: 31693562
[TBL] [Abstract][Full Text] [Related]
7. Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
Aguirre C; Meca-Lallana V; Barrios-Blandino A; Del Río B; Vivancos J
Mult Scler Relat Disord; 2020 Sep; 44():102250. PubMed ID: 32531754
[TBL] [Abstract][Full Text] [Related]
8. [Cases of pregnancy in patients with aggressive multiple sclerosis treated with natalizumab].
Yakushina TI; Belova YA
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(2. Vyp. 2):94-97. PubMed ID: 31156247
[TBL] [Abstract][Full Text] [Related]
9. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
10. Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) program.
Kelm RC; Hagstrom EL; Mathieu RJ; Orrell KA; Serrano L; Mueller KA; Laumann AE; West DP; Nardone B
J Am Acad Dermatol; 2019 Mar; 80(3):820-821. PubMed ID: 30395915
[No Abstract] [Full Text] [Related]
11. Natalizumab treatment in multiple sclerosis: the experience from two Brazilian MS centers.
Oliveira EM; Simm RF; Dasic G; Morais MM; Perreira SL; Callegaro D
Arq Neuropsiquiatr; 2015 Sep; 73(9):736-40. PubMed ID: 26352489
[TBL] [Abstract][Full Text] [Related]
12. Cyclical suicidal ideation following natalizumab infusion for multiple sclerosis.
Nagesh O; Bastiampillai T; Fisher L; Mohan T
Aust N Z J Psychiatry; 2015 Jul; 49(7):668-9. PubMed ID: 25688123
[No Abstract] [Full Text] [Related]
13. Evolution of MRI appearances due to progressive multifocal leucoencephalopathy following natalizumab treatment for multiple sclerosis.
Campbell S; Kanodia AK; O'Riordan J
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25878241
[No Abstract] [Full Text] [Related]
14. Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.
Massey TH; Smith R; Sadiq S; Overton C; Pearson OR
Neurology; 2017 Feb; 88(7):711-713. PubMed ID: 28077489
[No Abstract] [Full Text] [Related]
15. Angiopoietin-like proteins in multiple sclerosis.
Al-Temaimi R; Cherian P; Abu-Farha M; Alroughani R
J Neuroimmunol; 2019 May; 330():31-34. PubMed ID: 30784773
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
Dallari S; Franciotta D; Carluccio S; Signorini L; Gastaldi M; Colombo E; Bergamaschi R; Elia F; Villani S; Ferrante P; Delbue S
J Neuroimmunol; 2015 Oct; 287():76-9. PubMed ID: 26439965
[TBL] [Abstract][Full Text] [Related]
17. Hindsight is 20/20.
Moffett AT; Hollander H; Berkenblit G; McArthur JC; Manesh R
J Hosp Med; 2020 Apr; 15(4):245-249. PubMed ID: 32118562
[No Abstract] [Full Text] [Related]
18. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
[TBL] [Abstract][Full Text] [Related]
19. Detection of JCPyV microRNA in blood and urine samples of multiple sclerosis patients under natalizumab therapy.
Giovannelli I; Martelli F; Repice A; Massacesi L; Azzi A; Giannecchini S
J Neurovirol; 2015 Dec; 21(6):666-70. PubMed ID: 25678142
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab for multiple sclerosis: the dilemma of NOVA.
Hellwig K
Lancet Neurol; 2022 Jul; 21(7):579-581. PubMed ID: 35483388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
